exRNA Therapeutics
exRNA Therapeutics Limited, based in Bodhgaya, India, is a revolutionary biotech company focused on research and development. Established in 2021, it originated from Vastu Vihar Biotech, founded in 2014, which specialized in antisense therapy using natural antisense transcripts and RNA interference mechanisms. With a team of around 100 dedicated professionals, we excel in various areas of drug development, including bioinformatics for in-silico analysis, neurology, cardiology, rare diseases, autoimmune diseases, molecular analysis, and preclinical studies. Our lab meets BSL-2 standards, animal house with ethical committee, institutional biosafety committee; ensuring the highest quality in drug development. Securing multiple certifications significantly enhances our biotech research company’s credibility and operational standards. Our registration under 2196/PO/Rc/S/2022/CPCSEA for the animal house facility, demonstrates our compliance with the stringent ethical and welfare guidelines set by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA). This assures our stakeholders of our commitment to humane and responsible animal research practices. Additionally, the DSIR certification (TU/IV-RD/4586/2024) validates our in-house R&D capabilities, enabling us to benefit from various governmental incentives and support for scientific research, fostering innovation and enhancing our research output. Moreover, our ISO 9001:2015 certification for our R&D lab and theranostics underscores our dedication to quality management systems. This certification not only ensures that our processes and products meet the highest international standards but also increases our competitiveness in the global market.
Our Vision
At exRNA Therapeutics Limited, we envision a future where tailored RNA/DNA formulations become the bedrock of transformative treatments, offering hope and healing to those facing the challenges of rare diseases. Our dedication to pioneering science and unwavering commitment to patients drive our pursuit of innovative nucleic acid therapeutics. Our mission is clear - to propel RNA/DNA based innovations from the lab to the forefront of patient care. We strive to push the boundaries, developing novel RNA formulations and vehicles that hold the promise of improved outcomes and enhanced quality of life for individuals confronting rare diseases.
Innovation Unveiled
Inspired by nature’s tRNA fragments, we harness the remarkable potential of RNA to develop next-generation formulations and delivery systems. These are designed to target the intricate molecular pathways underlying diseases. Our relentless pursuit of innovation fuels our quest to transform the treatment landscape, one breakthrough at a time, through antisense therapy by targeting mRNA.
Facilities
Pre-Clinical Studies
exRNA Therapeutics preclinical lab facility is fully compliant with regulatory guidelines, ensuring the highest standards in research excellence. Our lab is equipped with cutting -edge tools for comprehensive preclinical testing, including advanced molecular and cellular analysis.
Meet Our team
Use this section to briefly introduce the members of your team.
Vinay Kr. Tiwary
Chief Managing Director
Satyam Tiwary
Chief Executive Officer
Dr. Rohit Kumar
Chief Scientist
Dr. Vivek Dwivedi
Chief Scientist
